Analysts/Institutional Investor Meet/Con. Call Updates

November 1, 2026 To, To, Listing/Compliance Department Listing/Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai – 400 001. G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. BSE CODE : 524208 NSE Symbol : AARTIIND Dear Sir/Madam, Sub.: Results Presentation Ref.: Regulation 30 of the SEBI (LODR) Regulations, 2015. Please find enclosed herewith the Q2 FY27 Results Presentation of the Company for your records Kindly take the same on record. Yours faithfully, FOR AARTI INDUSTRIES LIMITED RAJ SARRAF COMPANY SECRETARY ICSI M. NO. A15526 Encl.: As above. Q2 & H1 FY27 Performance Update 1st Nov 2026 Disclaimer AARTI INDUSTRIES LIMITED may, from time to time, make written and oral forward-looking statements, in addition to statements contained in the company's filings with BSE Limited [BSE] and National Stock Exchange of India Limited [NSE], and our reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the AARTI INDUSTRIES LIMITED. All information contained in this presentation has been prepared solely by AARTI INDUSTRIES LIMITED. AARTI INDUSTRIES LIMITED does not accept any liability whatsoever for any loss, howsoever, arising from any use or reliance on this presentation or its contents or otherwise arising in connection therewith. Agenda Company Overview Q2 & H1 FY27 Highlights 03 Future Outlook and Roadmap Agenda Company Overview Q2 & H1 FY27 Highlights 03 Future Outlook and Roadmap Aarti Industries at a Glance • Established by first generation technocrats in 1984 100+ 1100+ • Specialised in Benzene and Toluene based derivatives Products Domestic & Global Customers • Integrated operations and high-cost optimisation Exporting Manufacturing Plants • Key value chains include Nitro Chloro Benzenes, Countries Di-Chlorobenzenes, Phenylenediamines, Nitro Toluene Value 5,800+ Zero Liquid Employees Discharge Plants Chain and Sulphuric Acid & downstream State-of-the-art Co-generation • Strong R&D capabilities R&D Centers Power Plants • Strategically located in western India with proximity to ports VISION PURPOSE MISSION To emerge as a Global Partner of Right Chemistry for a Brighter Delighted Stakeholders Choice for leading consumers of Tomorrow speciality chemicals and intermediates CARE INTEGRITY EXCELLENCE Agenda Company Overview Q2 & H1 FY27 Highlights 03 Future Outlook and Roadmap Business Highlights Q2 FY27 Sustainability Partnerships Volumes Growth Cost Savings Digital & AI • AIL was awarded the • Existing Long-Term • Fuel Additives • Generating value by • Building inhouse most prestigious contracts Capacity expansion implementing various capability of Digital and Sword of Honor by progressing well from 290 to 360 kTPA cost savings initiatives Analytics by British Safety and remain stable completed in July 2026 catalysed by use of democratizing these skills Council for its R&D digital and advanced to improve efficiency, • Augene JV under • Overall volume growth Unit placing AIL analytics focused on reliability & overall commissioning trial across various product amongst the select yield and reliability productivity and ramp-up from portfolios few chemical improvement, energy H2 FY27 • Propelling AI adoption in companies globally to efficiency, etc. our workspace; 50+ have got this award. GenAI use cases executed over last Quarter Unlocking high-value manufacturing opportunities at Zone IV Commissioning of Phase I of Zone IV Strengthening downstream integration, application diversification and flexible manufacturing capabilities Key Highlights Strategic Benefits Next Milestone • Phase I commissioned: • Portfolio enhancement: Focus on commercial Calcium Chloride, PEDA and Strengthens Agrochemical qualification, customer part of the Multipurpose Plant and various other Speciality approvals and disciplined (MPP) are now operational Chemical-related offerings ramp-up, with progressive commercialisation of all • Deeper downstream • Application Zone IV manufacturing integration: diversification: blocks targeted during PEDA extends AIL’s existing Opportunities across FY27 Ethylation platform into agrochemicals, value-added products pharmaceuticals, coatings, polymers, etc • Flexible manufacturing: MPP enables • R&D to commercial-scale production commercialisation: of multiple products and Enhances the integrated advanced chemistries R&D, process scale-up and manufacturing ecosystem • New product opportunities: Several products planned from Zone IV are expected to be manufactured in India for the first time Long-term strategic manufacturing partnership Aarti Industries Enters into a 10+ Year Strategic Manufacturing & Supply Agreement Long-term partnership with a global speciality chemical company, creating sustained revenue visibility and future growth opportunities Key Deal Highlights: • Dedicated manufacturing and supply arrangement spanning 10+ years. • Estimated cumulative revenue of approximately ₹1,500 crore (~US$150 million) over the contract period. • AIL to set up, commission and operate a manufacturing facility in India using the customer’s proprietary process technology. • Customer led financing for CAPEX of less than US$25 million. • Operations expected to commence in FY29. Strategic Significance: • Adds a new global customer to AIL’s portfolio. Leverages AIL’s process scale-up, engineering and manufacturing capabilities. • Supports customer localisation and supply-chain resilience in India. Creates a platform to deepen the relationship as the customer’s India requirements grow. Q2 & H1 FY27 Highlights (Consolidated) ₹ in Cr Revenue increased due to YoY: 73%▲ QoQ: 48%▲ YoY: 44%▲ QoQ: 9%▲ YoY: 60%▲ QoQ: 9%▲ Overall volume growth coupled with passing-on of elevated input prices to customers. Volume Growth Energy Non-Energy YoY: 57%▲ YoY: 19%▲ QoQ: 51%▲ QoQ: 7%▲ Energy volumes increased across various Revenue EBITDA PAT geographies viz USA, EU, MENA and India YoY : 58%▲ YoY : 58%▲ YoY : 117%▲ Consolidated EBIDTA at ₹418 crs vs Standalone EBIDTA of ₹459 crs. This gap is due to an incremental provision for stock reserve created at Consolidated levels in respect of the In-transit inventories, which are yet to be delivered to the end customers Other Factors Working capital and debt increased due to increase in input prices. As a result, finance costs is higher 1100 > 85% Capacity utilization for major product groups 65 - 85% < 65% Product Groups Capacity (in KTPA) FY25 FY26 Q1 FY27 Q2 FY27 NCB 108 DCB 120 Hydrogenation 60 PDA 12 NT 45 Ethylation 25 - 30 Methylation (Fuel additives) 360 (from July 2026) Fuel Additives DCB Debottlenecking NT & Ethylation PDA Outlook Capacity DCB volumes increase NT and Ethylation capacity PDA capacity utilization Capacity expansion from supported by PDCB and utilization driven by MEA, impacted on account of 290 to 360 KTPA downstream demand; DEA demand; Expected to subdued US demand and completed further capacity improve in CY26 with DEA competition from China debottlenecking to 140 downstream integration KTPA underway investment (PEDA) and increasing demand outlook for MEA 1111 Revenue by End Use Agrochemicals & Fertilizers (12%) Demand remained steady; however weak monsoon might have impact in H2 Dyes, Pigments & Printing Inks (12%) Dyes, Pigment & Printing Inks segment delivered steady growth mostly driven by robust domestic demand Energy Application (50%) Strong global demand driven by high refining margins and robust gasoline-naphtha cracks; revenue share increase also driven by price increase driven by higher RM costs Pharma Applications (13% Share) Revenue growth driven mostly by price and volume increase in PNCB Polymer & Additives (10% Share) Impacted due to PDA chain softness; expected to improve in Q3 FY27 driven by DCB demand 1122 Application wise market updates & business highlights (1/2) Domestic [Showing first 8,000 characters — download PDF for full document]